{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T14:10:36Z","timestamp":1784124636456,"version":"3.55.0"},"reference-count":19,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T00:00:00Z","timestamp":1783641600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p>In China, advanced pancreatic cancer (PC) is known as the \u201cking of cancers\u201d due to its high treatment difficulty and extremely short survival period. Currently, advanced pancreatic cancer is mainly treated with chemotherapy. The 5-year survival rate is approximately 14.4% for patients with locally advanced pancreatic cancer and only 3% for those with distant metastasis. There are currently no effective targeted drugs for pancreatic cancer. This article reports a case of a patient with advanced pancreatic cancer harboring an EGFR exon 19 deletion. The patient received furmonertinib as third-line therapy, achieving a progression-free survival (PFS) of 6.3\u00a0months. Subsequently, drug resistance occurred; increasing the dose of furmonertinib showed no efficacy. Later, a combination of furmonertinib and anlotinib was administered, which successfully overcame the resistance. After follow-up, the patient passed away at home on 22 January 2026. The overall survival time was approximately 38\u00a0months. This case suggests that furmonertinib may be effective in patients with pancreatic cancer patients harboring an EGFR exon 19 deletion and that the combination of anlotinib and furmonertinib may overcome resistance to furmonertinib. This is only a case report, and these findings warrant further investigation.<\/jats:p>","DOI":"10.3389\/fphar.2026.1761167","type":"journal-article","created":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T07:31:13Z","timestamp":1783668673000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Furmonertinib demonstrated efficacy in a case of advanced pancreatic cancer with a 19-exon deletion mutation and wild-type KRAS: a case report and literature review"],"prefix":"10.3389","volume":"17","author":[{"given":"Fengcai","family":"Du","sequence":"first","affiliation":[{"name":"Departments of Oncology, The Affiliated Yantai Yuhuangding Hospital of Qingdao University","place":["Yantai, Shandong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan","family":"Liu","sequence":"additional","affiliation":[{"name":"Departments of Oncology, The Affiliated Yantai Yuhuangding Hospital of Qingdao University","place":["Yantai, Shandong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aihong","family":"Jiao","sequence":"additional","affiliation":[{"name":"Departments of Oncology, The Affiliated Yantai Yuhuangding Hospital of Qingdao University","place":["Yantai, Shandong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lulu","family":"Xu","sequence":"additional","affiliation":[{"name":"Departments of Oncology, The Affiliated Yantai Yuhuangding Hospital of Qingdao University","place":["Yantai, Shandong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,7,10]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/caac.21834","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J. Clin."},{"key":"B2","doi-asserted-by":"publisher","first-page":"1844","DOI":"10.1001\/jama.2016.4324","article-title":"Effect of chemoradiotherapy vs chemotherapy on survival in patients with locally advanced pancreatic cancer controlled after 4 months of gemcitabine with or without erlotinib: the LAP07 randomized clinical trial","volume":"315","author":"Hammel","year":"2016","journal-title":"JAMA"},{"key":"B25","article-title":"62P: Firmonertinib (formerly furmonertinib) combined with anlotinib in patients with treatment-naive EGFR-mutant non-small-cell lung cancer: updated results from FOCUS-a study","author":"Han","year":"2025","journal-title":"ELCC"},{"key":"B3","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1056\/NEJMoa1917239","article-title":"KRAS(G12C) inhibition with sotorasib in advanced solid tumors","volume":"383","author":"Hong","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"B4","doi-asserted-by":"publisher","first-page":"4711","DOI":"10.1200\/JCO.23.00222","article-title":"Flashback foreword: erlotinib and gemcitabine in pancreatic cancer","volume":"41","author":"Ko","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"2175","DOI":"10.3390\/biomedicines12102175","article-title":"Targeted therapies in pancreatic cancer: a new era of precision medicine","volume":"12","author":"Li","year":"2024","journal-title":"Biomedicines"},{"key":"B6","doi-asserted-by":"publisher","first-page":"1151178","DOI":"10.3389\/fonc.2023.1151178","article-title":"Advanced pancreatic cancer with KRAS wild-type and EGFR-sensitive mutation respond favorably to furmonertinib: a case report","volume":"13","author":"Ma","year":"2023","journal-title":"Front. Oncol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"1960","DOI":"10.1200\/JCO.2006.07.9525","article-title":"Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the national cancer institute of Canada clinical trials group","volume":"25","author":"Moore","year":"2007","journal-title":"J. Clin. Oncol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"2913","DOI":"10.1158\/0008-5472.CAN-14-0155","article-title":"Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States","volume":"74","author":"Rahib","year":"2014","journal-title":"Cancer Res."},{"key":"B9","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1007\/s00520-022-07564-8","article-title":"Systemic oncological treatments in patients with advanced pancreatic cancer: a scoping review and evidence map","volume":"31","author":"Salazar","year":"2023","journal-title":"Support Care Cancer"},{"key":"B10","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1016\/S2213-2600(20)30455-0","article-title":"Efficacy, safety, and genetic analysis of furmonertinib (AST2818) in patients with EGFR T790M mutated non-small-cell lung cancer: a phase 2b, multicentre, single-arm, open-label study","volume":"9","author":"Shi","year":"2021","journal-title":"Lancet Respir. Med."},{"key":"B11","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1016\/S2213-2600(22)00168-0","article-title":"Furmonertinib (AST2818) versus gefitinib as first-line therapy for Chinese patients with locally advanced or metastatic EGFR mutation-positive non-small-cell lung cancer (FURLONG): a multicentre, double-blind, randomised phase 3 study","volume":"10","author":"Shi","year":"2022","journal-title":"Lancet Respir. Med."},{"key":"B26","doi-asserted-by":"crossref","first-page":"S1651","DOI":"10.1016\/j.annonc.2024.10.691","article-title":"Furmonertinib 160mg as first-line treatment for advanced non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) exon 21 L858R mutation","volume":"35","author":"Shi","year":"2024","journal-title":"Ann. Oncol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21654","article-title":"Cancer statistics, 2021","volume":"71","author":"Siegel","year":"2021","journal-title":"CA Cancer J. Clin."},{"key":"B13","doi-asserted-by":"publisher","first-page":"12","DOI":"10.3322\/caac.21820","article-title":"Cancer statistics, 2024","volume":"74","author":"Siegel","year":"2024","journal-title":"CA Cancer J. Clin."},{"key":"B14","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1056\/NEJMoa2208470","article-title":"Sotorasib in KRAS p.G12C-Mutated advanced pancreatic cancer","volume":"388","author":"Strickler","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"B15","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J. Clin."},{"key":"B16","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1038\/s41401-021-00692-7","article-title":"Furmonertinib (alflutinib, AST2818) is a potential positive control drug comparable to rifampin for evaluation of CYP3A4 induction in sandwich-cultured primary human hepatocytes","volume":"43","author":"Wu","year":"2022","journal-title":"Acta Pharmacol. Sin."},{"key":"B17","doi-asserted-by":"publisher","first-page":"3093","DOI":"10.1097\/CM9.0000000000003442","article-title":"Comparative analysis of cancer statistics in China and the United States in 2024","volume":"137","author":"Wu","year":"2024","journal-title":"Chin. Med. J. Engl."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1761167\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T13:26:57Z","timestamp":1784122017000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1761167\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,10]]},"references-count":19,"alternative-id":["10.3389\/fphar.2026.1761167"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2026.1761167","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,10]]},"article-number":"1761167"}}